New‐onset vitiligo and progression of pre‐existing vitiligo during treatment with biological agents in chronic inflammatory diseases

• DOI: 10.1111/jdv.13759
• Publication Date: 2016-06-13T05:22:57Z
• Authors: L. Méry‐Bossard; K. Bagny; G. Chaby; A. Khemis; F. Maccari; H. Marotte; J.L. Perrot; Z. Reguiai; M.L. Sigal; M. Avenel‐Audran; T. Boyé; A. Grasland; J. Gillard; D. Jullien; E. Toussirot
• Keywords: Vitiligo; Ustekinumab; Abatacept; Tocilizumab; Biological drugs

Abstract Background The development of vitiligo during treatment with biological agents is an unusual event and only a few isolated cases have been reported. Objectives To describe the clinical characteristics evolution patients developing new‐onset following initiation agent for chronic inflammatory disease; also to report course pre‐existing under therapy. Methods This nationwide multicentre, retrospective study, carried out between July 2013 January 2015, describes large series 18 (psoriasis N = 8, rheumatic diseases ulcerative colitis 1, uveitis 1) who developed while receiving agent. Results TNF α inhibitors were most common involved (13/18) anti‐ IL ‐12/23 ‐17 or abatacept less (4/18 1/18 respectively). Mean duration exposure before onset was 13.9 ± 16.5 months. Outcome favourable (15/17) maintaining Data collected 5, 10, bowel 2, SAPHO had when started ( 15, ustekinumab rituximab tocilizumab 1). Vitiligo progressed in seven stable improved eight cases. Conclusion may thus emerge and/or progress various agents, mainly could be new paradoxical skin reaction. De novo displays outcome agent, whereas prognosis seems worse vitiligo.